Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
José Adán Ortega Blanco holds a patent portfolio in the Biotechnology & Pharmaceuticals technology area. There is currently 1 pending office action associated with this portfolio. The prosecution is centralized, involving 1 distinct examiner and a distinct art unit. This suggests that the intellectual property being sought is highly specialized and fits within a specific niche of the biotechnology field. The limited number of pending actions indicates a very targeted approach to patent acquisition. This focused strategy suggests that the entity is currently prioritizing a specific technical solution.
The busiest examiner for this portfolio is BREEN, KIMBERLY CATHERINE, who has 1 pending office action. As this is the only pending action for the portfolio, this examiner oversees all current activity. Practitioners can expect a focus on the requirements of this specific art unit and examiner. Without other pending matters to balance the workload, the progress of the entire portfolio is currently subject to the timeline and examination style of this individual. Success in this matter will require a thorough understanding of the examiner's specific concerns. The practitioner should prioritize clear communication and technical precision to address any potential rejections within this specialized art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BREEN, KIMBERLY CATHERINE | 1 | 23.8% | +56.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18267990 | METHOD FOR PRODUCING HUMAN COLLAGEN STRUCTURES WITH CONTROLLED CHARACTERISTICS | BREEN, KIMBERLY CATHERINE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18267990 | METHOD FOR PRODUCING HUMAN COLLAGEN STRUCTURES WITH CONTROLLED CHARACTERISTICS | BREEN, KIMBERLY CATHERINE | — |
| Art Unit | Apps |
|---|---|
| 1657 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18267990 | METHOD FOR PRODUCING HUMAN COLLAGEN STRUCTURES WITH CONTROLLED CHARACTERISTICS | BREEN, KIMBERLY CATHERINE | 1657 | §103§112 | Final Rejection | — | Pending | Jun 16, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialJosé Adán Ortega Blanco has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Kimberly Catherine Breen has the most, with 1 of José Adán Ortega Blanco's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
